Skip to content
OpenCapital
Get started

Haemonetics HAE Plasma — Goodwill

Other segment segments

Hospital
$600.44M+9.5%
Blood Center
$26.89M-0.3%

Similar metrics at other companies

Ashland logo
ASHLife Sciences — Goodwill
$462M-42.8%
Sunbelt Rentals Holdings logo
SUNBSpecialty — Goodwill
$1.11B+6.6%
Gentex logo
GNTXOther — Goodwill
$34.74M—
Knife River logo
KNFWest — Goodwill
$137.88M+11.5%
Parsons Corporation logo
PSNCritical Infrastructure — Goodwill
$324.87M+8.1%
FTI Consulting logo
FCNCorporate Finance — Goodwill
$542.4M+1.0%

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.31B-18.0%

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's plasma — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's plasma — goodwill?
Haemonetics (HAE) reported plasma — goodwill of $29.04M in Q1 2026.
How has Haemonetics's plasma — goodwill changed year-over-year?
Haemonetics's plasma — goodwill decreased by 0.0% year-over-year, from $29.04M to $29.04M.
What does plasma — goodwill mean?
Represents the intangible asset value recorded when the purchase price of an acquired business in the plasma sector exceeds the fair value of its identifiable net assets. This metric reflects the premium paid for expected future synergies and market positioning. It is subject to periodic impairment testing to ensure the carrying value remains supported by future cash flows.